201. Group-Based Trajectory Modeling of N-Terminal Pro-Brain Natriuretic Peptide Levels in Pulmonary Artery Hypertension Associated with Connective Tissue Disease.
- Author
-
Tang, Heng, Lu, Fengyun, Huang, Yingheng, Wang, Qiang, Sun, Xiaoxuan, Zhang, Miaojia, and Zhou, Lei
- Subjects
ADRENOCORTICAL hormones ,IMMUNOSUPPRESSIVE agents ,RESEARCH funding ,SCIENTIFIC observation ,IMMUNOTHERAPY ,MULTIPLE regression analysis ,FISHER exact test ,RHEUMATOID arthritis ,PEPTIDE hormones ,RETROSPECTIVE studies ,DISEASE remission ,DESCRIPTIVE statistics ,SYSTEMIC lupus erythematosus ,MANN Whitney U Test ,CHI-squared test ,CONNECTIVE tissue diseases ,ODDS ratio ,KAPLAN-Meier estimator ,MEDICAL records ,ACQUISITION of data ,SYSTEMIC scleroderma ,NEUROPSYCHOLOGICAL tests ,PULMONARY arterial hypertension ,CONFIDENCE intervals ,DATA analysis software ,SJOGREN'S syndrome ,GROUP process ,DISEASE complications - Abstract
Group-based trajectory modeling (GBTM) allows the trajectory analyses of repeated N-terminal pro-brain natriuretic peptide (NT-proBNP) measurements during follow-up visits of pulmonary artery hypertension associated with connective tissue disease (CTD-PAH) patients. This study aimed to (1) identify trajectories of NT-proBNP changing over time, (2) explore the association between NT-proBNP trajectories and prognosis, and (3) explore the effects of baseline clinical characteristics on NT-proBNP trajectories. A retrospective, single-centred, observational study was performed on 52 CTD-PAH patients who had undergone at least three follow-up visits within 1 year from baseline. Four NT-proBNP trajectories were identified using GBTM: low stability (n = 15, 28.85%), early remission (remission within 3 months) (n = 20, 38.46%), delayed remission (remission after 6 or 9 months) (n = 11, 21.15%), and high stability (n = 6, 11.54%). The low-stability and early-remission trajectories were related to a similar positive prognosis, while the delayed-remission and high-stability trajectories were associated with a gradually worsening prognosis (p = 0.000). Intensive CTD immunotherapy (corticosteroids plus immunosuppressants) was the only factor that remained significant after least absolute shrinkage and selection operator regression and multivariate logistic regression, and was independently associated with a lower risk NT-proBNP trajectory (p = 0.048, odds ratio = 0.027, 95% confidence interval: 0.001–0.963), which preliminarily indicated a benefit of CTD-PAH patients undergoing intensive CTD immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF